Clinical Trial Update: A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve [Phase 3]

View source ↗

Summary

This Phase 3 trial compares luspatercept against epoetin alfa for treating anemia in ESA-naïve patients with IPSS-R very low/low/intermediate risk myelodysplast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• EPOETIN ALFA (EPOETIN ALFA)
• Luspatercept (luspatercept)

Snippet

Sponsor: Celgene | Conditions: Myelodysplastic Syndromes | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-06-26